EUVIMEDEUVIMED entdecken
Multizentrische Studie

COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance

Mohammad Javad Najafzadeh iD, Tahmineh Shaban, Hossein Zarrinfar, Alireza Sedaghat, Neginsadat Hosseinikargar, Fariba Berenji, Mahsa Jalali, Michaela Lackner, Jasper Elvin James, Macit Ilkit iD, Cornelia Lass-Flörl

Medical Mycology · 2024

DOI: 10.1093/mmy/myae031 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Medical Mycology, 2024. Verfasst von Mohammad Javad Najafzadeh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Candidemia, COVID-19. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Elite Researcher Grant Committee, Mashhad University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our understanding of fungal epidemiology and the burden of antifungal drug resistance in COVID-19-associated candidemia (CAC) patients is limited. Therefore, we conducted a retrospective multicenter study in Iran to explore clinical and microbiological profiles of CAC patients. Yeast isolated from blood, were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and subjected to antifungal susceptibility testing (AFST) using the broth microdilution method M27-A3 protocol. A total of 0.6% of the COVID-19 patients acquired CAC (43/6174). Fluconazole was the most widely used antifungal, and 37% of patients were not treated. Contrary to historic candidemia patients, Candida albicans and C. tropicalis were the most common species. In vitro resistance was high and only noted for azoles; 50%, 20%, and 13.6% of patients were infected with azole-non-susceptible (ANS) C. tropicalis, C. parapsilosis, and C. albicans isolates, respectively. ERG11 mutations conferring azole resistance were detected for C. parapsilosis isolates (Y132F), recovered from an azole-naïve patient. Our study revealed an unprecedented rise in ANS Candida isolates, including the first C. parapsilosis isolate carrying Y132F, among CAC patients in Iran, which potentially threatens the efficacy of fluconazole, the most widely used drug in our centers. Considering the high mortality rate and 37% of untreated CAC cases, our study underscores the importance of infection control strategies and antifungal stewardship to minimize the emergence of ANS Candida isolates during COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CandidemiaCOVID-19HumansAntifungal AgentsFluconazoleAzolesMicrobial Sensitivity TestsCandidaCandida albicansCandida tropicalisCandida parapsilosisDrug Resistance, Fungal

Stichwörter der Autor:innen

Candida parapsilosisERG11COVID-19-associated candidemiaY132Fazole resistance

Substanzen

Antifungal AgentsFluconazoleAzoles

Autor:innen und Institutionen

  • Department of Medical Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Lung Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
  • Division of Mycology, Faculty of Medicine, Çukurova University, Adana, Türkiye.

ORCID-Profile: Mohammad Javad Najafzadeh, Macit Ilkit

Förderung

  • Elite Researcher Grant Committee
  • Mashhad University of Medical Sciences

Zitieren

APA

Najafzadeh, M. J., Shaban, T., Zarrinfar, H., Sedaghat, A., Hosseinikargar, N., Berenji, F., Jalali, M., Lackner, M., James, J. E., Ilkit, M., & Lass-Flörl, C. (2024). COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance. Medical Mycology. https://doi.org/10.1093/mmy/myae031

Vancouver

Najafzadeh MJ, Shaban T, Zarrinfar H, Sedaghat A, Hosseinikargar N, Berenji F, et al. COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance. Medical Mycology. 2024. doi:10.1093/mmy/myae031

BibTeX
@article{Najafzadeh2024,
  author = {Najafzadeh, Mohammad Javad and Shaban, Tahmineh and Zarrinfar, Hossein and Sedaghat, Alireza and Hosseinikargar, Neginsadat and Berenji, Fariba and Jalali, Mahsa and Lackner, Michaela and James, Jasper Elvin and Ilkit, Macit and Lass-Flörl, Cornelia},
  title = {COVID-19 associated candidemia: From a shift in fungal epidemiology to a rise in azole drug resistance},
  journal = {Medical Mycology},
  year = {2024},
  doi = {10.1093/mmy/myae031}
}
Kostenlos starten →